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Opinion statement
Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies character-
ized by variable but most often indolent biologic behavior. Well-differentiated NETs
can be broadly classified as either carcinoid or pancreatic NET. Although they have sim-
ilar characteristics on routine histologic evaluation, the 2 tumor subtypes have differ-
ent biology and respond differently to treatment, with most therapeutic agents
demonstrating higher response rates in pancreatic NETs compared with carcinoid. Until
recently, systemic treatment options for patients with advanced NETs were limited.
However, improvements in our understanding of signaling pathways involved in the
pathogenesis, growth, and spread of NETs have translated into an expansion of treat-
ment options. Aberrant signaling through the mechanistic pathway of rapamycin
(mTOR) pathway has been implicated in neuroendocrine tumorigenesis. Additionally,
altered expression of mTOR pathway components has been observed in NETs and has
been associated with clinical outcomes. Targeting the mTOR pathway has emerged as
an effective treatment strategy in the management of advanced NETs. In a randomized,
placebo-controlled study of patients with advanced pancreatic NET, treatment with the
mTOR inhibitor everolimus was associated with improved progression-free survival
(PFS). Largely based upon these data, everolimus has been approved in the United
States and Europe for the treatment of patients with advanced pancreatic NET. The ac-
tivity of everolimus remains under investigation in patients with carcinoid tumors. In a
randomized study of patients with advanced carcinoid tumors associated with carcinoid
syndrome, the addition of everolimus to octreotide was associated with improved PFS
compared with octreotide. However, the results did not meet the prespecified level of
statistical significance based on central review of radiographic imaging. Results from a
randomized study examining the efficacy of everolimus in patients with nonfunctional
gastrointestinal and lung NETs are awaited. In addition, further investigation is needed
to determine whether primary tumor site or other clinical and molecular factors can im-
pact response to mTOR inhibition. Although everolimus can slow tumor progression,
significant tumor reduction is rarely obtained. Targeting multiple signaling pathways
is a treatment strategy that may provide better tumor control and overcome resistance
mechanisms involved with targeting a single pathway. Results of ongoing and future
studies will provide important information regarding the added benefit of combining
mTOR inhibitors with other targeted agents, such as VEGF pathway inhibitors, and cy-
totoxic chemotherapy in the treatment of advanced NETs.
Introduction
Neuroendocrine tumors (NET) are a rare and het-
erogeneous group of neoplasms that arise from
neuroendocrine cells located throughout the body.
These tumors are characterized by their ability to
secrete peptides resulting in distinctive hormonal
syndromes. NETs consist of a spectrum of disease
ranging from well-differentiated, low-grade tumors
to poorly differentiated, high-grade carcinomas
[1•, 2]. In general, poorly differentiated, high-
grade carcinomas represent aggressive cancers that
have a different natural history and response to
treatment compared with well-differentiated, low-
grade NETs.
A number of different complex classification sys-
tems exist for grading NET pathology [1•]. In the
2010 World Health Organization (WHO) classifica-
tion, neuroendocrine neoplasms of the digestive sys-
tem are categorized as low-grade (G1), intermediate-
grade (G2), and high-grade (G3) based upon mitotic
count and proliferative index (Ki-67) [3]. High grade
carcinomas are those with a mitotic count of 920 per
10 high powered fields (HPF) or a Ki-67 proliferation
index of 920 %. High grade carcinomas have a more
aggressive biology and are generally treated with plat-
inum-based chemotherapy regimens used to treat
small cell lung cancer. In contrast, well-differentiated,
low- and intermediate-grade NETs have a more indo-
lent biology and lower measures of cell proliferation.
Wel l -d i f f e rent i a ted NETs can be broadly
subclassified as either carcinoid or pancreatic NETs.
Carcinoid tumors may arise from multiple different
organs and historically have been classified according
to site of embryonic origin, namely foregut (gastric,
bronchial), midgut (small intestine, appendix, proxi-
mal large bowel), and hindgut (distal colon, rectum,
genitourinary) [4]. While carcinoid and pancreatic
NETs may have similar histologic characteristics, these
2 tumor subtypes have different biology and respond
differently to therapy, with most agents demonstrating
higher response rates in pancreatic NET patients com-
pared with carcinoid.
When NETs are diagnosed at an early stage, surgical
resection is often curative. Unfortunately, curative sur-
gery is rarely an option for patients with metastatic dis-
ease. Recent studies have demonstrated that in
addition to improving symptoms related to hormone
hypersecretion, somatostatin analogs slow disease pro-
gression in patients with small bowel carcinoid tumors
and gastrointestinal neuroendocrine tumors, including
pancreatic NET [5, 6]. Treatment approaches with
targeted therapy, including the use of agents inhibiting
the vascular endothelial growth factor (VEGF) and
mTOR signaling pathways and other pathways involved
in neuroendocrine tumorigenesis, also provide new ther-
apeutic options for patients with NET [7, 8••].
Notably, there are a subset of patients with NETs that
appear histologically well- or moderately differentiated
but are associated with Ki-67 proliferation indices
920 % that fall into the high-grade range. The most ap-
propriate therapy for this subgroup of patients has not
been well established. A recent series of patients with
high-grade gastrointestinal neuroendocrine carcinomas
demonstrated that response rates to platinum-based che-
motherapy were lower in patients with a Ki-67 G55 %
[9]. Because sensitivity to platinum-based chemotherapy
appears to be associated with higher Ki-67 proliferation
rates, other cytotoxic agents, such as temozolomide, or
targeted agents, such asmTOR inhibitors or angiogenesis
inhibitors, may play a role in the management of the
management of these patients.
The aim of this review is to provide an overview of
the role of the mTOR pathway in the pathogenesis of
neuroendocrine tumors and to review the role of
mTOR inhibitors in the treatment of this disease.
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The mTOR pathway
The mechanistic target (originally referred to as “mammalian target”) of
rapamycin (mTOR) is an intracellular serine/threonine kinase that regulates
key cell functions involved in cell survival, proliferation, and metabolism.
mTOR interacts with several proteins to form 2 multiprotein complexes re-
ferred to as mTOR complex 1 (mTORC1) and 2 (mTORC2) [10]. By inte-
grating signals from growth factors and nutrients, mTOR regulates various
anabolic and catabolic cellular processes [11, 12•, 13].
mTORC1, which is the better characterized of the 2 complexes, is activat-
ed by extracellular growth factors and nutrients (Fig. 1). When active,
mTORC1 phosphorylates the translational regulators eukaryotic initiation
factor 4E (eIF4E) binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1). These
events lead to cell proliferation by promoting translation of specific mRNAs
encoding proteins regulating cell-cycle progression, angiogenesis, energy
metabolism, and metastasis [14]. mTORC1 also promotes lipid biosynthesis
and suppresses autophagy through phosphorylation of other key cellular
effectors [12•].
Compared with mTORC1, less is known about mTORC2. It also responds
to growth factor signals, and when active, mTORC2 regulates cell survival,
cytoskeletal remodeling, and cell migration [15, 16]. It also serves to regulate
Fig. 1. The mTOR signaling pathway. Simplified representation of key components of the mTOR signaling network. The mTOR
pathway plays an important role in mediating growth factor signals that stimulate cell growth and proliferation and regulate
angiogenesis and cell metabolism. Arrows represent activation; bars represent inhibition. Adapted from Yao et al, 2013 [66].
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the PI3K/AKT pathway via phosphorylation and activation of Akt [17].
Whereas mTORC1 is sensitive to inhibition by rapamycin, mTORC2 is
considered insensitive to rapamycin [12•].
In addition to regulation by energy and nutrient status, the mTOR path-
way responds to growth factors through signaling involving the phos-
phatidylinositol 3-kinase (PI3K) pathway (Fig. 1) [13]. Binding of insulin or
insulin-like growth factors to their receptors leads to phosphorylation of
insulin receptor substrate (IRS). PI3K is subsequently recruited to the cell
membrane, leading to phosphorylation of phosphatidylinositiol-4,5-
bisphospate (PIP2) to phosphatidylinositiol-3,4,5-bisphospate (PIP3), and
ultimately activation of Akt. The phosphatase PTEN is an inhibitory regulator
of the PI3K-Akt-mTOR pathway that antagonizes the action of PI3K by de-
phosphorylating PIP3 to PIP2, causing suppression of PI3K-dependent cell
signaling.
mTOR is linked to the PI3K-Akt pathway by the tuberous sclerosis pro-
teins TSC1 and TSC2, which act as a heterodimer that negatively regulates
mTOR signaling. In response to insulin and other growth factors, TSC2 is
phosphorylated and inactivated by Akt, which then leads to mTOR activation
[18–20].
The mTOR pathway and pathogenesis of NET
Several observations support the importance of the mTOR pathway in the
pathogenesis of NET. First, although most NETs arise sporadically, NETs can
arise within the context of several familial cancer syndromes that are due to
mutations in genes encoding proteins that lie upstream from mTOR. Neu-
rofibromatosis type 1 (NF-1) and tuberous sclerosis (TS) are autosomal
dominant tumor susceptibility syndromes caused by inactivating mutations
in the tumor suppressor genes NF1 and TSC1 and TSC2, respectively [21].
NF1 encodes the protein neurofibromin, which regulates TSC1 and TSC2
[22]. Loss of NF1 in neurofibromatosis leads to constitutive activation of
mTOR and is associated with NETs involving the ampulla of Vater, duode-
num, and mediastinum. Loss of function of TSC1 and TSC2 leads to mTOR
activation in patients with tuberous sclerosis, which has been associated with
pancreatic NETs [23].
Second, whole exome sequencing analysis of sporadic pancreatic NETs
has identified somatic mutations in genes involved in the mTOR pathway,
including PTEN, TS2, and PIK3CA, in 15 % of cases [24•]. Additionally,
chromosomal changes, including loss of 16p, the region containing TSC2,
and loss of 10q, which contains PTEN, have been reported in pancreatic NET
[25, 26].
Altered expression of mTOR pathway components also has been observed
in NETs and has been associated with clinical outcomes in several studies. In
an analysis of gene expression profiles of 72 primary pancreatic NETs, TSC2
and PTEN were found to be downregulated in most of the primary tumors
[27•]. In this study, 85 % of primary tumors showed altered protein levels of
TSC2, PTEN, or both. Low levels of expression of TSC2 and PTEN were as-
sociated with shorter disease-free and overall survival. Moreover, 8/25
(32 %) patients with low levels of TSC2 and PTEN developed liver metas-
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tases and progression of disease compared with none of 20 patients with
normal levels of both TSC2 and PTEN. Studies have also demonstrated that
expression of mTOR and its downstream targets are associated with clinical
outcome [28, 29•]. In an analysis of tumor from 195 patients with NETs
arising in various sites, primarily small intestine, expression of mTOR or its
activated downstream target p-EIF4EBP1 was associated with a higher pro-
liferative index. Furthermore, high expression of mTOR or its activated
downstream products were associated with shorter survival [29•].
Interestingly, there appears to be differential expression of mTOR depend-
ing on the primary tumor site. Expression levels of mTOR and activation of
its downstream targets have been found to be higher in foregut tumors
compared with midgut tumors [28]. Additionally, although low expression
of PTEN, TSC1, and TSC2 have been found in pancreatic NETs, TSC1 and
TSC2 expression appear preserved in small intestinal NET [29•]. This suggests
that there may be potential differences in the mechanisms of mTOR activa-
tion in different subgroups of NETs.
Treatment
Targeting the mTOR pathway
& The mTOR inhibitor rapamycin and its analogs bind FK506 binding
protein, and this complex binds to mTORC1, inhibiting downstream
signaling [30]. Everolimus and temsirolimus are rapamycin deriva-
tives that have been evaluated in the treatment NET (Tables 1 and 2).
Everolimus
Pancreatic NET
& The activity of everolimus in pancreatic NET was explored in the
RADIANT-1 trial, an international multicenter phase II trial of 160
Table 1. Clinical trials of mTOR inhibitors in carcinoid tumors








Everolimus a 30 17 63 wk Yao et al. 2008 [37]




Everolimus + octreotide LAR vs. 216 2 16.4 mo Pavel et al. 2011[38••]





PFS progression-free survival, TTP time to progression
a Data from the subset of patients with carcinoid tumors in these phase II studies of unselected patients with NET are presented
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patients, 45 of whom also received concurrent treatment with octreotide
at the discretion of investigators [31]. Upstream regulation of the IGF
pathway is thought to be a potential resistancemechanism for everolimus
[32, 33]. Because octreotide has been shown to reduce serum IGF-1 levels
in patients with advanced solid tumors, the use of everolimus plus a so-
matostatin analog to target both upstream and downstream components
of the mTOR pathway has been postulated to potentially have greater
efficacy than single agent therapy. Among patients receiving octreotide
plus everolimus, median PFS was longer compared with those receiving
everolimus alone (17 vs 9.7 months). However, whether the addition
octreotide to everolimus contributed to higher PFS is uncertain since the
study was not randomized or designed to make this comparison.
& Everolimus monotherapy subsequently was compared with best
supportive care alone in the placebo-controlled RADIANT-3 trial,
which included 410 patients with advanced pancreatic NET [8••].
Approximately 40 % of patients also received somatostatin analog
therapy. Everolimus was associated with a significant prolongation in
median PFS (11.0 vs 4.6 months, hazard ratio [HR] for progression
0.35, 95 % confidence interval [CI] 0.27–0.45). Confirmed objective
partial radiographic responses were observed in 5 % of patients re-
ceiving everolimus compared with 2 % of those receiving placebo.
The rate of tumor stabilization was high, 73 % among patients re-
ceiving everolimus vs 51 % in the placebo group.
& Drug-related adverse among patients with pancreatic NET receiving
everolimus included stomatitis, rash, diarrhea, and fatigue [8••]. The
most common grade 3 or 4 drug-related adverse events were sto-
Table 2. Clinical trials of mTOR inhibitors in Pancreatic NET tumors








Everolimusa 30 27 50 wk Yao et al. 2008 [37]
RADIANT-1 Everolimus 115 9 9.7 mo Yao et al. 2010 [31]
Everolimus + octreotide 45 4 16.7 mo
Temsirolimusa 15 7 10.6 mo Duran et al. 2006 [41]
Phase III studies
RADIANT-3 Everolimus vs. 207 5 11 mo Yao et al. 2011[8••]
Placebo 203 2 4.6 mo
CALGB 80701 Everolimus + octreotide vs. Ongoing
Everolimus + bevacizumab
+ octreotide
PFS progression-free survival, TTP time to progression
a Data from the subset of patients with pancreatic NET in this phase II study of unselected patients with NET are presented
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matitis (7 %), anemia (6 %), and hyperglycemia (5 %). Though rare,
everolimus has been associated with serious, adverse events, in-
cluding pneumonitis.
& Everolimus causes hyperglycemia, particularly in those with pre-
existing hyperglycemia. In the RADIANT-3 trial, the frequency of
severe (grade 3 or 4) hyperglycemia was higher in those with pre-
existing diabetes mellitus or baseline hyperglycemia (15 % vs 3 % in
those without diabetes or baseline hyperglycemia) [34]. Because of
this effect, everolimus may be of particular value in patients with
hypoglycemia related to insulinoma [35, 36]. In 1 report, 4 patients
with malignant insulinoma and refractory hypoglycemia experienced
normalization of glucose levels while receiving everolimus [35]. Two
of these patients had an objective radiographic antitumor response,
which may have led to improvements in insulin secretion. Clinical
improvement in the 2 patients with stable disease suggests a possible
direct effect of everolimus on insulin production and/or release or an
effect on peripheral insulin sensitivity.
Carcinoid tumors
& Everolimus has been evaluated in combination with octreotide in a
phase II study of patients with advanced NETs. Partial responses were
observed in 5 of 30 (17 %) patients with carcinoid tumors, with a
median PFS of 63 weeks in this group of patients [37].
& The activity of everolimus was further investigated in patients with
functional NET in the randomized, placebo-controlled RADIANT-2 trial
[38••]. In this study, 429 patients with advanced NETs associated with
carcinoid syndrome and radiographic disease progression in the pre-
ceding 12months were randomly assigned to octreotide LAR with either
everolimus or placebo. Half of patients had a primary small bowel tu-
mor; lung primary tumors were the second most common tumor type.
Themedian PFS as assessed by central radiology reviewwas 16.4months
for patients receiving everolimus and octreotide LAR compared with
11.3months for patients receiving placebo and octreotide LAR (HR 0.77,
95%CI 0.59–1.00;P=0.026). These results did notmeet the prespecified
level of statistical significance. However, based on local investigator ra-
diology assessment, combined therapywas associatedwith amedianPFS
duration of 12.0 months compared with 8.6 months with placebo (HR
0.78, 95 % CI 0.62–0.98; P=0.018). Additionally, imbalances in prog-
nostic variables favoring the control group, including disease site and
performance status, could have affected the primary outcome results. A
subsequent analysis found a significant PFS benefit for everolimus after
adjusting for randomization imbalances (HR for progression 0.62, 95%
CI 0.51–0.87, P=0.003) [39].
& The best overall radiographic response was a partial response in 2 %
of both groups; stable disease was the best response in 84 % of the
patients treated with everolimus and 81 % of patients receiving
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placebo [38••]. Patients treated with everolimus had a higher rate of
biochemical responses. SerumchromograninA levels decreased in46%
of patients receiving everolimus compared with 36 % of patients re-
ceiving placebo, and 24 hour urinary 5-hydroxyindoleacetic acid (5-
HIAA) excretion decreased in 61 % of patients receiving everolimus
compared with 54 % of patients receiving placebo. Data on control of
symptoms related to carcinoid syndrome were not reported.
& Additional studies are also needed to determine whether primary tumor
site of originmay impact response to everolimus. Patients with advanced
colorectal NET have a particularly poor prognosis. In a post-hoc analysis
of the RADIANT-2 study, patients with colorectal NETs receiving evero-
limus plus octreotide LAR had significantly longer PFS (29.9 mo; n=19)
compared with those receiving placebo plus octreotide LAR (6.6 mo; n=
20) [40]. Furthermore, some degree of tumor shrinkage was more fre-
quently noted in patients receiving everolimus plus octreotide LAR
compared with those receiving placebo plus octreotide LAR (67 % vs
37 %).
& The RADIANT-4 trial, a phase III study in which patients with ad-
vanced, nonfunctional lung or gastrointestinal NETs were random-
ized to receive everolimus or placebo, recently completed accrual
(clinical trials.gov, NCT01524783). The results of this study will
provide important information regarding the activity of everolimus
in the treatment of nonpancreatic NET.
Temsirolimus
& The single-agent activity of temsirolimus was evaluated in a multicenter
phase II study of 37 patients with advanced, progressive neuroendocrine
tumors [41]. Although the intent-to-treat response rate for the cohort was
low (6 %), 54 % of patients experienced stable disease while on treatment
with a median time to progression (TTP) of 6 months. Higher baseline
tumor levels of phosphorylated mTOR predicted for better outcomes. Fur-
thermore, temsirolimus appeared more active in patients with pancreatic
NET comparedwith carcinoid;median TTP in patients with pancreatic NET
was 10.6 months compared with 6 months in the carcinoid subgroup.
However, the small size of this study limits definite conclusions regarding
the impact of primary tumor site on efficacy of temsirolimus.
Future directions with mTOR inhibitor therapy
& Rapamycin and its derivatives are generally cytostatic rather than
cytotoxic. One of the factors contributing to their limited clinical
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success is the existence of multiple feedback loops regulating cell
survival (Fig. 1). Under normal circumstances, mTORC-1 activation
of S6K1 promotes degradation of insulin receptor substrate (IRS),
leading to attenuation of PI3K signaling. Inhibition of mTORC1 can
lead to increased PI3K signaling by relieving this negative feedback
[33, 42]. In addition, mTORC1-mediated signaling can inhibit
mTORC2 through phosphorylation of rictor, one of the components
of mTORC2. By blocking this feedback loop, rapamycin can con-
tribute to mTORC2-mediated AKT activation. Furthermore, studies
have also demonstrated that inhibition of the PI3K/AKT/mTOR
pathway can result in activation of other receptor tyrosine kinases,
resulting in downstream signaling promoting cell growth [43].
& Targeting multiple signaling pathways may provide better tumor
control and overcome resistance mechanisms. Combining an mTOR
inhibitor with somatostatin analogs, inhibitors of the VEGF pathway
and cytotoxic chemotherapy have been evaluated as treatment
strategies for NETs.
Combining mTOR inhibitor and somatostatin analog
& Because octreotide has been shown to decrease IGF-1 levels and
PI3K/Akt signaling in vitro, it has been postulated that combining
an mTOR inhibitor with a somatostatin analog might result in
enhanced antitumor activity [44]. Everolimus has been evaluated
in combination with octreotide in several studies, including pa-
tients with pancreatic NET in stratum 2 of the RADIANT-1 trial
and patients with carcinoid tumors in the phase III RADIANT-2
trial. In the RADIANT-1 trial, patients receiving octreotide and
everolimus had longer PFS compared with patients receiving
everolimus monotherapy [31]. However, the study was not ran-
domized or designed to make this comparison. In the RADIANT-2
trial, although combined therapy with everolimus and octreotide
was associated with a significantly longer PFS duration compared
with everolimus and placebo based on local investigator radiology
review, the improvement in PFS was not statistically significant
according to central radiology review [38••]. Further investigation
is needed to determine whether there are specific subsets of pa-
tients with advanced NETs who benefit most from the addition of
everolimus to octreotide.
& Pasireotide is a novel somatostatin analog that binds to a broader
range of somatostatin receptor subtypes (sst) than octreotide. Com-
pared with octreotide, pasireotide has a greater binding affinity to
sst1, sst3, and sst5 and comparable affinity with sst2 [45]. Increased
receptor binding may lead to additional antiproliferative activity and
Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors Chan and Kulke 373
growth inhibition in NET [44]. A phase I study has established the
feasibility of combining pasireotide and everolimus [46]. Hypergly-
cemia was a commonly observed toxicity. A partial radiographic tu-
mor response was noted in 1/21 patients (5 %), and 17/21 (81 %)
experienced at least some tumor regression as the best response to
therapy. The COOPERATE-2 study, a multi-center randomized phase
II study, recently completed accrual and has examined the combi-
nation of everolimus alone or in combination with pasireotide LAR
in patients with advanced, progressive pancreatic NET (clinical
trials.gov, NCT01374451). The results of this study will provide ad-
ditional information regarding the added efficacy of combining an
mTOR inhibitor with a somatostatin analog.
Combining mTOR inhibitor and VEGF pathway inhibitor
& A key role for angiogenesis and VEGF pathway signaling in NET is sug-
gested by clinical observations that neuroendocrine tumors are vascular
tumors. Expression of VEGF has been demonstrated in carcinoid and
pancreatic NETs [47, 48]. Increased expression of VEGF receptor-2
(VEGFR-2) has been demonstrated in tissue from gastrointestinal carci-
noid tumors and a carcinoid cell line [49, 50]. Additionally, pancreatic
neuroendocrine tumors also show widespread expression of VEGFR-2
and -3 in addition toplatelet-derived growth factor receptors (PDGFRs)α
and β, stem-cell factor receptor (c-kit) [51–53].
& The tyrosine kinase inhibitor sunitinib has shown activity against a
range of signaling pathways and growth factors/receptors, including
VEGFR-1, -2 and -3, PDGFR-α and -β, KIT, RET, FMS-like tyrosine
kinase-3 (FLT3), and colony-stimulating factor receptor (CSF-1R). In
a randomized phase III study examining the activity of sunitinib in
patients with progressive pancreatic NET, sunitinib was associated
with a median progression-free survival (PFS) of 11.4 months, as
compared with 5.5 months for placebo (PG .001) [7]. Two other
small molecule tyrosine kinase inhibitors (TKIs), sorafenib, and
pazopanib, have also been evaluated in phase II studies [54, 55].
Although response rates to TKIs in carcinoid tumors have been low,
all studies report a high rate of disease stabilization and potentially
encouraging progression-free survival durations.
& Bevacizumab, a monoclonal antibody against VEGF, has been eval-
uated in a randomized phase II study of patients with advanced or
metastatic carcinoid tumors on a stable dose of octreotide. Patients
were randomly assigned to receive 18 weeks of bevacizumab or
pegylated IFN-α 2b [56]. During the first 18 weeks of therapy, 18 %
of the bevacizumab-treated patients experienced radiographic partial
responses, and 77 % had stable disease. Furthermore, after 18 weeks,
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95 % of patients treated with octreotide plus bevacizumab remained
progression-free compared with only 68 % of those receiving
octreotide plus IFN-α.
& A number of recently completed and ongoing studies have evaluated
the combination of an mTOR inhibitor with inhibitors of the VEGF
pathway. Combining everolimus with tyrosine kinase inhibitors of
VEGFR and other growth factor receptors may be limited by toxicity.
In a phase I study of everolimus in combination with sorafenib,
dose-limiting toxicity precluding escalation to full doses of each
agent was observed [57]. However, the combination of the everoli-
mus and bevacizumab was shown to be well tolerated and associated
with antitumor activity (overall response rate 26 %) in an initial
phase II study enrolling patients with low or intermediate grade
neuroendocrine tumors [58]. Furthermore, encouraging early results
have been noted in a phase II trial of temsirolimus plus bevacizumab
in 55 patients with progressive NET. In a preliminary report, a con-
firmed partial response was documented in 20 patients (37 %), and
44 (80 %) remained progression-free at 6 months [59]. Results of
CALGB 80701, a phase II trial of patients with advanced pancreatic
NETs randomized to receive either everolimus and octreotide or
everolimus plus bevacizumab and octreotide, will provide additional
information about the benefits of combined mTOR and VEGF
pathway inhibition (clinical trials.gov, NCT01229943).
Combining mTOR inhibitor and cytotoxic chemotherapy
& Cytotoxic chemotherapy has minimal activity in patients with ad-
vanced carcinoid tumors. In contrast, pancreatic NETs may respond
well to treatment with streptozocin and other alkylating agents [60,
61]. Recent prospective and retrospective studies have suggested that
temozolomide-based regimens may be comparable in efficacy and
more tolerable than streptozocin-based regimens. In retrospective
series, temozolomide-based therapy has been associated with overall
response rates of 8 %–70 % in patients with advanced pancreatic
NET [62–64].
& The combination of temozolomide and everolimus has been evalu-
ated in a phase I/II study of patients with advanced pancreatic NET
[65]. Treatment was associated with known side effects of each drug
without evidence of synergistic toxicity. Encouraging evidence of
antitumor activity with this combination was observed. Among 40
evaluable patients, 16 (40 %) experienced a partial response. The
median PFS duration was 15.4 months, which is superior to the re-
ported PFS observed with everolimus alone in the randomized,
placebo-controlled RADIANT-3 study. However, these results need to
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be interpreted with caution since this was a single-arm study. Fur-
thermore, disease progression prior to study enrollment was not a re-
quirement in this study, as it was in the RADIANT-3 study. Future studies
evaluating the relative efficacy of combining chemotherapywith anmTOR
inhibitor compared with treatment with either agent alone are warranted.
Conclusions
Recent improvements in our understanding of the molecular biology of NETs
have led to an expansion of treatment options for patients with advanced
disease. Studies indicate that the mTOR pathway plays an important role in
the pathogenesis of NET. The mTOR inhibitor everolimus has been shown to
significantly delay disease progression in patients with pancreatic NET. Fur-
ther studies evaluating everolimus in advanced carcinoid are anticipated.
Results of ongoing and future studies will provide important information
regarding the added benefit of combining an mTOR inhibitor with cytotoxic
chemotherapy and other targeted agents, such as VEGF pathway inhibitors,
in the treatment of advanced NETs.
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